Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults

AIDS

Volumn 21, Issue 9, 2007, Pages 1137-1145

  Currier, Judith S ^a   Kendall, Michelle A ^b   Henry, W Keith ^c   Alston Smith, Beverly ^d   Torriani, Francesca J ^e   Tebas, Pablo ^f   Li, Yanjie ^g   Hodis, Howard N ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Carotid artery; HIV; Intima media thickness; Protease inhibitors

Indexed keywords

HOMOCYSTEINE; INDINAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD PRESSURE; CAROTID ARTERY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ECHOGRAPHY; ETHNICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MENOPAUSE; PRIORITY JOURNAL; RACE; SEX; SMOKING; STATISTICAL SIGNIFICANCE;

ADULT; ANTILIPEMIC AGENTS; CAROTID ARTERIES; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; METABOLIC SYNDROME X; PROSPECTIVE STUDIES; TUNICA INTIMA;

EID: 34248524639     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32811ebf79     Document Type: Article

References (42)

1. Mulligan K, Grunfeld C, Tai VW, Algran H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immun Defic Syndr 2000; 23:35-43.
2. Melroe NH, Kopaczewski J, Henry K, Huebsch J. Lipid abnormalities associated with protease inhibitors. J Assoc Nurses AIDS Care 1999; 10:22-30.
3. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63-F70.
4. Berthold HK, Parhofer KG, Ritter MM, Addo M, Wasmuth JC, Schliefer K, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Me 1999; 246:567-575.
5. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance due to HIV protease inhibitors. AIDS 1998; 12:F51-F58.
6. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
7. Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr Opin Lipidol 2001; 12:313-319.
8. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193.
9. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-2982.
10. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045-1052.
11. Dubé MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000; 31:1467-1475.
12. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50:1378-1388.
13. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351:871-875.
14. Shor Posner G, Basit A, Lu Y, Cabrejos C, Chang J, Fletcher M, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993; 94:515-519.
15. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R. Elevated levels of CD38+CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1993; 6:904-912.
16. Henry K, Zackin R, Dubé M, Hammer S, Sprecher D, Currier J. C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS 2004; 18:2434-2437.
17. Dolan SE, Hadigan C, Killilea KM, Sullivan MP, Hemphill L, Lees RS, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005; 39:44-54.
18. Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ, Visscher B, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006; 166:64-70.
19. Holmberg SD, Moorman AC, Greenberg AE. Trends in rates of myocardial infarction among patients with HIV. N Engl J Med 2004; 350:730-732.
20. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2001; 17:2479-2486.
21. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
22. Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani FJ, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005; 19:927-933.
23. Hodis H, Mack W, Lobo R, Shoupe D, Sevanian A, Mahrer P, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135:939-953.
24. Hodis H, Mack W, LaBree L, Selzer RH, Liu CR, Liu CH, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998:262-269.
25. Selzer RH, Hodis HN, Kwong-Fu H, Mack WJ, Lee PL, Liu CR, et al. Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound images. Atherosclerosis 1994; 111:1-11.
26. Selzer RH, Mack WJ, Lee PL, Kwong-Fu H, Hodis HN. Improved common carotid elasticity and intima-media thickness measurements from computer analysis of sequential ultrasound frames. Atherosclerosis 2001; 154:185-193.
27. Lehmann E. Nonparametrics: Statistical Methods based on Ranks. San Francisco: Holden-Day; 1975.
28. Seminari E, Pan A, Voltini G, Carnevale G, Maserati R, Minoli L, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002; 162:433-438.
29. Mercie P, Thiebaut R, Lavignolle V, Pellegrin JL, Yvorra-Vives MC, Morlat P, et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002; 34:55-63.
30. Maggi P, Serio G, Epifani G, Fiorentino G, Saracino A, Fico C, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000; 14:F123-F128.
31. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, et al. Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS 2001; 15:329-334.
32. Chironi G, Escaut L, Gariepy J, Cogny A, Teicher E, Monsuez JJ, et al. Brief report: carotid intima-media thickness in heavily pretreated HIV-infected patients. J Acquir Immune Defic Syndr 2003; 32:490-493.
33. Jerico C, Knobel H, Calvo N, Sorli ML, Guelar A, Gimeno-Bayon JL, et al. Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy. Stroke 2006; 37:812-817.
34. Mercie P, Thiebaut R, Aurillac-Lavignolle V, Pellegrin JL, Yvorra-Vives MC, Cipriano C, et al. Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients. HIV Med 2005; 6:380-387.
35. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603-1608.
36. de Saint Martin L, Vandhuick O, Guillo P, Bellein V, Bressollette L, Roudaut N, et al. Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis 2006; 185:361-367.
37. Mangili A, Gerrior J, Tang AM, O'Leary DH, Polak JK, Schaefer EJ, et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Clin Infect Dis 2006; 43:1482-1489.
38. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-2022.
39. Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol 2002; 31:59-70.
40. Willinek WA, Ludwig M, Lennarz M, Holler T, Stumpe KO. High-normal serum homocysteine concentrations are associated with an increased risk of early atherosclerotic carotid artery wall lesions in healthy subjects. J Hypertens 2000; 18:425-430.
41. Bernasconi E, Uhr M, Magenta L, Ranno A, Telenti A. Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. AIDS 2001; 15:1081-1082.
42. Uccelli MC, Torti C, Lapadula G, Labate L, Cologni G, Tirelli V, et al. Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART. Ann Nutr Metab 2006; 50:247-252.